Nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. [3] The mechanism of action of nafamostat is as a slow tight-binding substrate, trapping the target protein in the acyl-enzyme intermediate form, resulting in apparent observed inhibition.

2016年10月20日 · Nafamostat is a fast-acting proteolytic inhibitor used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin by competitively inhibiting several serine proteases including thrombin.

Nafamostat is a fast-acting proteolytic inhibitor used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin by competitively inhibiting several serine proteases including thrombin. It improves acute pancreatitis and prevents blood clot formation during extracorporeal circulation and has an anti-inflammatory effect in vitro.

2023年10月18日 · Nafamostat mesylate is a potent in vitro antiviral agent that inhibits the host transmembrane protease serine 2 enzyme used by severe acute respiratory syndrome coronavirus 2 for cell entry.

This study aims to establish a whole body intravenous PBPK model of nafamostat in adults and to scale down the adult PBPK model to children and provide pediatric exposures of nafamostat for different age groups and suggest an optimal weight-based nafamostat dose in …

2021年5月12日 · Nafamostat demonstrated antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and we evaluated its clinical potential in hospitalised patients with Coronavirus disease 2019 (COVID-19) pneumonia.

A synthetic protease inhibitor, nafamostat mesylate (INN) or nafamostat, ultimately blocks human cell entry of SARS-CoV-2, activity validated by in-vitro studies. Nafamostat inhibits platelet aggregation, thrombin, kallikrein, plasmin, and other complement factors and …